Information Provided By:
Fly News Breaks for November 9, 2018
ISR
Nov 9, 2018 | 08:20 EDT
As reported earlier, Maxim analyst Jason McCarthy downgraded IsoRay to Hold from Buy after its Q4 results saw a sequential decline of 2.5%. The analyst maintains his view that the company's "Cs-131 is a superior isotope for radio-therapy", but also notes that it continues to struggle to drive revenue growth. McCarthy adds that it is too early to tell whether its GammaTile be the answer, but only sees incremental revenue growth from the program.
News For ISR From the Last 2 Days
There are no results for your query ISR